STK25 Loss Augments Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Stability in Colorectal Cancer

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Tumor immune evasion hinders anti-cancer immunotherapy efficacy.
• Serine/threonine protein kinase 25 (STK25) is implicated in neoplastic diseases, but its role in colorectal cancer (CRC) is unknown.

Purpose of the Study:

• To investigate the function of STK25 in the colorectal cancer microenvironment.
• To determine STK25's role in regulating tumor immune evasion and immunotherapy response.

Main Methods:

• Utilized STK25 global knockout (STK25-/-) and tumor-bearing knockout mice models.
• Analyzed PD-L1 protein levels, ubiquitination status, and T cell infiltration.
• Correlated STK25 expression with patient response to immune checkpoint blockade (ICB) therapy.

Main Results:

• STK25 deficiency enhanced anti-PD-1 immunotherapy effectiveness, leading to significant tumor suppression.
• STK25 knockout increased CD8+ T cell recruitment to tumors.
• STK25 deficiency stabilized PD-L1 protein by regulating K48-linked ubiquitination via NEDD4.

Conclusions:

• STK25 plays a critical role in regulating PD-L1 protein stability and tumor immune evasion in CRC.
• Targeting STK25 may represent a novel strategy to improve ICB therapy sensitivity in colorectal cancer patients.